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ABSTRACT 
Background 
Echocardiographic screening is under consideration as a disease control strategy for 
rheumatic heart disease (RHD). However, clinical outcomes of young people with screening-
detected RHD are unknown. We aimed to describe the outcomes for a cohort with screening-
detected RHD, in comparison to patients with clinically-diagnosed RHD. 
Methods 
A retrospective cohort study included all young people with screening-detected RHD in the 
Central Division of Fiji in the primary cohort. Screen-negative and clinically-diagnosed 
comparison groups were matched 1:1 to the primary cohort. Data were collected on mortality, 
clinical complications and healthcare utilisation from the electronic and paper health records 
and existing databases. 
Results 
Seventy participants were included in each group. Demographic characteristics of the groups 
were similar (median age 11 years, 69% female, median follow-up 7 years). There were nine 
(12.9%) RHD-related deaths in the clinically-diagnosed group and one (1.4%) in the 
screening-detected group (Incident Rate Ratio: 9.6, 95% CI 1.3–420.6). Complications of 
RHD were observed in 39 (55.7%) clinically-diagnosed cases, four (20%) screening-detected 
cases and one (1.4%) screen-negative case. There were significant differences in the 
cumulative complication curves of the groups (p<0.001). Rates of admission and surgery 
were highest in the clinically-diagnosed group, and higher in the screening-detected than 
screen-negative group. 
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Conclusions 
Young people with screening-detected RHD have worse health outcomes than screen-
negative cases in Fiji. The prognosis of clinically-diagnosed RHD remains poor, with very 
high mortality and complication rates. Further studies in other settings will inform RHD 
screening policy. Comprehensive control strategies are required for disease prevention.  
Abstract Word Count: 248 
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Rheumatic heart disease; mass screening; echocardiography; complications; morbidity; 
mortality; survival analysis  
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1. INTRODUCTION 
Rheumatic heart disease (RHD) is the chronic sequel of acute rheumatic fever (ARF), an 
autoimmune reaction to infection with the Group A Streptococcus bacterium. People with 
RHD are at increased risk of complications such as congestive heart failure (CHF), infective 
endocarditis, arrhythmia, stroke, complications of pregnancy and childbirth, and premature 
death. 
Echocardiography is a sensitive test for the diagnosis of RHD (1). Screening using 
echocardiography may identify individuals with RHD that have not previously presented to 
clinical services, and echocardiographic screening research activities have been conducted in 
many countries for two decades (2, 3). There are an estimated 33 million prevalent cases of 
RHD globally (4), although this estimate does not include asymptomatic cases as uncovered 
in screening studies, suggesting the actual global burden may be considerably greater (5). 
However, whilst data exist on the natural history of RHD for patients presenting with 
clinically-diagnosed ARF or RHD (6), data are limited on the clinical outcomes for people 
with screening-detected RHD. It is therefore not known whether echocardiographic findings 
on screening represent only trivial to mild disease, or if some predispose to serious 
complications, increased healthcare utilisation and premature death. These data are required 
for development of evidence-based policy for population-level screening. 
We previously reported severe disease on echocardiography in some young people with 
screening-detected RHD in Fiji (7). In this study, we aimed to describe the clinical outcomes 
for a cohort of young people with screening-detected RHD, and to compare these outcomes 
to a cohort without RHD and to a cohort with clinically-diagnosed RHD.  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 6 
2. METHODS 
2.1 Design and setting 
We used a retrospective cohort study to describe and compare the clinical outcomes of a 
screening-detected RHD cohort with two matched groups of screen-negative and clinically-
diagnosed RHD participants. 
This study took place in the Central Division of Fiji, a country in the South Pacific with a 
population of approximately 900,000. Forty-one percent of the population reside in the 
Central Division (8). Fiji has a very high prevalence of RHD (definite RHD 7 per 1000 
school-aged children on echocardiography) (9). Fiji has conducted sporadic 
echocardiographic screening for RHD since 2006 and has an active RHD control program 
managed by the Ministry of Health and Medical Services.  All inpatient and outpatient 
medical care for children and young adults with RHD in the Central Division is provided at 
the Colonial War Memorial Hospital in Suva. 
2.2 Participants 
Cases were defined by interrogating a database compiled from individual screening activity 
logs in Fiji, as previously described (10). All young people aged 5 – 15 years who were 
diagnosed with RHD on echocardiographic screening from 2006 – 2013 and recommended to 
commence secondary prophylaxis were included in the primary cohort (11-13). We excluded 
any child known to have RHD prior to screening, or who was later assessed to have a non-
RHD diagnosis such as congenital heart disease. We also excluded cases assessed to have 
possible or probable RHD (14) or borderline RHD (15). We excluded cases screened outside 
the Central Division as data for other divisions were unreliable or unavailable.  
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We then defined two matched comparison groups: a control group of screen-negative 
participants, and a comparison group of participants with clinically-diagnosed RHD. 
Participants for these groups were matched 1:1 for each screening-detected case by date of 
screening/diagnosis, age, gender and ethnicity. Screen-negative cases were identified by 
manually searching the school screening enrolment logs for the child of the closest age to the 
case at the same school, where gender and ethnicity were matched. Echocardiography reports 
were then checked to ensure none had congenital or other abnormalities 
Clinically-diagnosed cases were identified by manually searching the Fiji National RHD 
register. At the time of the study, the register was a locally-stored, Microsoft Access database 
managed by the RHD control program, containing demographic and clinical information for 
all cases of ARF and RHD notified to the program since 2005. Patients without RHD 
(registered as ARF only) or residing outside the Central Division were excluded. Register 
data were filtered to display age and gender matched individuals with a clinical diagnosis 
date within 12 months of the screening date of the screening-detected case. The individual 
with the closest age was enrolled as the match. In the few instances where there was no 
available match for cases of other Pacific Islander ethnicity, a match was selected from the 
indigenous iTaukei population. Matching was performed blinded to any additional clinical or 
demographic information. 
2.3 Outcomes 
The study period was defined from the date of screening or clinical diagnosis until July 31 
2015, or the date of death where applicable. Outcomes collected were known clinical 
complications of RHD (CHF, infective endocarditis, stroke, ARF recurrence, and death). 
Data were also collected on healthcare utilisation episodes including admissions, surgery and 
medication prescriptions. Documented prescription of a medical treatment for cardiac failure 
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was coded as CHF. Reliable data were not available for complications of pregnancy and 
childbirth.  
2.4 Data collection 
The main data source was the Fiji electronic health information system (PATIS Plus) which 
includes hospital admission coding according to the International Statistical Classification of 
Diseases and Related Health Problems (ICD-10) for the main divisional and subdivisional 
hospitals nationally, and detailed medication prescribing records. Coding data for hospital 
admissions are fairly reliable, although there are some known deficiencies (16). The second 
major source of data was individual patient files held at the Colonial War Memorial Hospital. 
These paper files were manually inspected page-by-page for details of admissions, surgery, 
medications and complications. Additional data were extracted from the Fiji National RHD 
Register and existing lists of cardiac surgical cases held by the RHD control program. 
Two data collectors used a standardised data extraction tool to inspect the PATIS record, 
individual patient file and any other available data sources and reached consensus on items to 
include in the analysis. When assessing admission episodes for clinically-diagnosed cases, 
any admission where the initial diagnosis of RHD was made was excluded, and only 
subsequent admissions counted. All records were reviewed by an experienced paediatrician 
and reasons for admission, surgery and death were classified as RHD-related or not. 
A list of participants who had died was compiled from all data sources. We then undertook a 
primary review of death certificates held at the Fiji Health Information Unit to determine 
cause of death. Death certificate information is generally available and reliable as reporting 
deaths is mandatory prior to burial or cremation (17).  
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2.5 Statistical analysis 
Descriptive statistics were used to calculate frequency of clinical outcomes. Incident rates 
were calculated using the total period of observation of each group as the denominator. 
Incident rate ratios (IRR) with 95% confidence intervals were used to compare outcomes 
between the primary cohort (screening-detected) and the screen-negative and clinically-
diagnosed groups. Kaplan-Meier failure curves were used to compare mortality and 
cumulative RHD complications, and the log-rank test used to assess for differences between 
groups. Results were analysed using Stata 14.2 (Statacorp, College Station, TX, USA). 
2.6 Ethical approval  
The study protocol was approved by the Fiji National Research Ethics Review Committee 
(2014.134) and the Royal Children’s Hospital Human Research Ethics Committee, Australia 
(2015-02). 
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3. RESULTS 
3.1 Characteristics of cohort groups 
Seventy screening-detected cases were included. The median age at screening was 10.9 years, 
median age at end of study was 17.6 years and median length of observation was 7.4 years. 
Females accounted for 69% of cases and 83% were iTaukei (indigenous Fijian). These cases 
were matched with 70 screen-negative and 70 clinically-diagnosed cases, and the 
demographic characteristics of the three groups were very similar (Table 1). 
3.2 Healthcare interactions 
There were 28 admissions (16 RHD-related) in the screening-detected group compared to 4 
(none RHD-related) in the screen-negative group and 113 (78 RHD-related) in the clinically-
diagnosed group (Table 2). Admission incident rates were higher in the screening-detected 
than screen-negative group (IRR 7.1, 95% CI 2.5–27.9) and higher in the clinically-diagnosed 
than screening-detected group for overall admissions (IRR 4.3, 95% CI 2.8–6.8) and RHD-
related admissions (IRR 5.2, 95% CI 3.0–9.5). Admission bed days were higher in the 
screening-detected than screen-negative group (IRR 3.7, 95% CI 2.7–5.3) and higher in the 
clinically-diagnosed than screening-detected group (IRR 6.6, 95% CI 5.6–7.8). 
Three screening-detected and fifteen clinically-diagnosed patients had cardiac valve surgery 
during the study. Surgical episodes were more frequent in the clinically-diagnosed group than 
the screening-detected group, both overall (IRR 7.5, 95% CI 2.6–29.2) and for RHD-related 
surgery (IRR 6.4, 95% CI 1.8–33.9, Table 2). There was only one episode of surgery (not 
RHD related) in the screen-negative group, although this result was not statistically 
significantly different to the screening-detected group with this sample size.  
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3.3 RHD complications 
In the screening-detected group, 14 (20%) developed complications of RHD, particularly 
CHF (Table 2). There was one episode each of infective endocarditis, arrhythmia and ARF 
recurrence. The rate of complications was significantly higher than the screen-negative group 
(IRR 14.2, 95% CI 2.2–601.9) where only one complication was recorded (idiopathic 
supraventricular tachycardia). Complications were most frequent in the clinically-diagnosed 
group (IRR compared to screening-detected group: 3.0, 95% I 1.6–5.9), with 39 (56%) 
cases developing complications, most commonly CHF (49%). There was a significant 
difference in the complication-free survival curves between the clinically-diagnosed and 
screening-detected group (p<0.001) and between the screening-detected and screen-negative 
groups (p<0.001, Fig. 1) 
3.4 Mortality 
There were two deaths (3%) in the screening-detected group, one due to RHD, which equates 
to an RHD-attributable death rate of 2.1 per 1000 person-years. There were nine deaths 
(13%) in the clinically-diagnosed group, all due to RHD, which equates to an RHD-
attributable death rate of 20.5 per 1000 person-years (IRR compared to screening-detected 
group for overall mortality: 4.8, 95% CI 1.0–45.6; for RHD-related mortality: 9.6, 95% CI 
1.3–420.6, Table 2). There were no deaths in the screen-negative group. There was a 
significant difference in the survival curves for mortality between the clinically-diagnosed 
and screening-detected groups (p=0.02) but not between the screening-detected and screen-
negative groups (p=0.16, Fig. 2).   Outcomes by sex are shown in Appendix Table A.1.
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4. DISCUSSION 
This cohort study provides several insights into the clinical outcomes of screening-detected 
and clinically-diagnosed RHD in this setting. Firstly, screening-detected RHD is associated 
with poorer health outcomes than for those without RHD, with a high complication rate of 
20% over a median follow-up of 7 years. The predominant complication was CHF, and there 
were episodes of arrhythmia and endocarditis, three cases requiring valve surgery and one 
death from severe RHD. This suggests a health burden clearly in excess of the general child 
and adolescent population of Fiji, as evidenced by the incident rate ratio 14 times higher for 
complications, and 7 times higher for admissions, compared to the screen-negative group. 
There were no deaths or RHD-related healthcare episodes in the screen-negative group, 
which precluded calculation of incident rate ratios for these outcomes. 
Secondly, we report a very high rate of complications in the clinically-diagnosed group, with 
more than half developing complications and a striking 13% mortality rate over the median 7 
years of follow-up. These data provide further evidence of the devastating nature and poor 
prognosis of clinical RHD, even in this young age-group. The clinically-diagnosed group was 
3 to 5 times more likely to develop complications or be admitted for RHD than the screening-
detected group, and 10 times more likely to die from RHD. These differences may be due to 
clinically-diagnosed cases having a more severe form of disease, a more advanced stage of 
disease, or more cases with true disease rather than benign echocardiographic abnormalities. 
There were few recorded episodes of ARF in either RHD group, although under-diagnosis 
and under-reporting are known to be issues in Fiji (18).  
There are few data on the clinical outcomes of screening-detected RHD available for 
comparison. Mirabel et al. followed 114 children with screening-detected RHD in New 
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Caledonia for a shorter period (median 2.5 years) and reported a mild spectrum of disease 
without significantly different outcomes to a matched screen-negative group (19). Only one 
child with screening-detected RHD developed heart failure and there were no deaths or 
episodes of cardiac surgery. In Uganda, two of 51 children with asymptomatic, screening-
detected RHD developed ARF, including one with CHF, over a median follow-up of 25 
months (20). In South Africa, two of 44 asymptomatic cases developed symptomatic CHF 
over five years (21). The differences between these studies and our results are consistent with 
the higher severity of the Fiji screening cohort on echocardiography (7) and may represent 
differences in the health systems and health-seeking behaviours of the population. It is likely 
that several screening-detected cases in our study who developed complications would have 
had clinical symptoms at time of diagnosis, and represent “missed” clinical cases rather than 
pre-symptomatic disease.  
The richest contemporary data on the outcomes of clinically-diagnosed RHD is the multi-
centre, prospective REMEDY cohort study which reported outcomes at 2 years for 3343 
patients in low and middle income countries in Africa, Yemen and India (22). The cohort was 
considerably older (median age 28 years) and half had severe disease at baseline. The 
mortality rate over two years was 17%. CHF was found in 33% at baseline and a further 7% 
developed CHF over 2 years. Age, severe disease and CHF at baseline were predictors of 
mortality. The outcomes from the present study are comparable with the REMEDY data, and 
likely represent an even poorer prognosis, given the Fiji cohort was considerably younger and 
was selected from all new clinically-diagnosed RHD cases rather than symptomatic, hospital-
based cases. A cohort of 396 new clinically-diagnosed cases of RHD admitted to a tertiary 
hospital in New Caledonia was also older than our cohort at baseline (median age 18 years, 
IQR 10-40). Cardiac complications were present in 27% at baseline (23). Of those followed 
for a median of 4 years, 2.4% died, a further 6% developed complications each year and 20% 
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required surgical or percutaneous intervention. A cohort of 1066 clinically-diagnosed, 
Indigenous RHD cases from the RHD registry of the Northern Territory of Australia (median 
age 22 years) found CHF in 14% at baseline and a further 13% within 5 years of diagnosis 
(24). All cause-mortality was 11.6% after 10 years in the Indigenous cohort, with a 
standardised mortality ratio of 1.56 compared to the Indigenous population of that region. By 
contrast, the all-cause mortality rate for all ARF/RHD patients in Fiji was previously 
estimated to be 3.7% per year (2% in 4-19 year olds).(17) In both the New Caledonian and 
Australian cohorts, outcomes were far poorer for those with severe disease, who had a low 
rate of complications. The better outcomes observed in Australia and New Caledonia, 
compared to REMEDY and Fiji cohorts may reflect the quality and availability of healthcare 
and surgical services, and the benefits of benefits of long-standing RHD control programs. 
The study findings suggest that screening-detected RHD represents an earlier, or less severe 
form of RHD, with poor health outcomes compared to the unaffected population. However, 
there is likely variation among this group, and some cases may never develop clinical disease. 
It remains unclear whether there are characteristics identifiable at the time of screening which 
may predict which patients are more likely to progress to clinical complications. This should 
be the target of future research, although large, prospective cohorts will be required. These 
results add to the growing body of evidence around early case detection, and specifically 
echocardiographic screening, for the prevention of RHD. This evidence will assist in ongoing 
formulation of RHD screening policy, including the development of economic analyses.  
4.1 Strengths and limitations 
We provide the longest follow-up data on outcomes following echocardiographic screening, 
and the first data from a developing country. The three, well-matched cohort groups allow 
comparison with the health utilisation and clinical outcomes of a non-affected population and 
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a clinically-diagnosed group. Data were collected from multiple sources. However, there are 
several limitations to this study. Reliable details of disease severity at diagnosis were 
unavailable, and therefore it is not possible to determine the effect of severity on the observed 
differences between the clinically-diagnosed and screening-detected groups, or between our 
cohort and other international cohorts. It is likely that some clinically-diagnosed cases were 
misdiagnosed as RHD due to a low threshold for diagnosis in children admitted for illnesses 
such as sepsis or ARF in this high RHD-prevalence setting, particularly prior to the 
development of the 2012 World Heart Federation diagnostic criteria (15). However, all cases 
were taken from the RHD register and had been commenced on antibiotic prophylaxis. This 
misclassification would likely underestimate the complication rate in this group. The sample 
size was limited by the number of screening-detected cases, and incidence estimates of 
complications and mortality may be imprecise, as demonstrated by the wide confidence 
intervals for some results. This study did not evaluate outcomes for those with screening-
detected borderline RHD, and the clinical prognosis of that group remains unclear. Data were 
collected retrospectively and limited by the availability and completeness of documentation. 
Due to data availability, participants were limited to those in the Central Division, and results 
may not be generalizable to more remote parts of Fiji or international settings.  
Finally, secondary antibiotic prophylaxis adherence data for were not available over the 
period of follow-up, and it is not known what effect prophylaxis would have on clinical 
outcomes. Adherence is generally low in Fiji (10), and the poor outcomes observed in both 
RHD groups underlines the need to improve secondary prophylaxis delivery structures for all 
known cases. Screening will be ineffective without high levels of adherence, and should not 
be implemented without the fundamentals of a register-based control program and strong 
health systems for secondary prophylaxis and follow-up. 
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5. CONCLUSIONS 
Young people with screening-detected, definite RHD in Fiji have worse health outcomes than 
screen-negative cases, with more morbidity and greater healthcare utilization. The prognosis 
of clinically-diagnosed RHD remains poor, with very high rates of mortality and 
complications. Further follow-up studies from a range of settings will inform RHD screening 
policy. Screening may detect sizeable numbers of cases who are either symptomatic at 
baseline or rapidly become so. Further studies from a range of settings are needed to guide 
how such patients should be managed and followed, and to inform broader RHD screening 
policy. Investment and implementation of comprehensive control strategies are required to 
prevent complications and mortality.  
Abbreviations 
ARF: acute rheumatic fever 
CHF: congestive heart failure 
RHD: rheumatic heart disease 
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TABLES AND FIGURES 
TABLE 1 – Characteristics of participant groups 
Characteristic 
Screening-
detected 
Screen-
negative 
Clinically-
diagnosed 
Median age at screening / diagnosis (IQR), yrs 10.9 (8.7, 12.4) 10.9 (8.8, 12.6) 10.9 (8.8, 12.9)  
Median age at end of study (IQR), yrs 17.6 (13.1, 20.1) 17.6 (13.1, 20.2) 17.8 (14.6, 20.2) 
Median length of observation (IQR), yrs 7.4 (6.9, 8.9) 7.4 (6.9, 8.9) 7.0 (5.1, 8.8) 
Sex – n (%)    
Male 22 (31.4) 22 (31.4) 22 (31.4) 
Female 48 (68.6) 48 (68.6) 48 (68.6) 
Ethnicity – n (%)    
iTaukei 58 (82.9) 60 (85.1) 59 (84.3) 
Fijian of Indian Descent  10 (14.3) 10 (14.3) 10 (14.3) 
Other 2 (2.9) 0 1 (1.4) 
Total 70 70 70 
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TABLE 2 – Clinical outcomes of screening-detected RHD patients in comparison to screen-negative and clinically-diagnosed groups 
Characteristic 
Screening-
detected 
(n = 70) 
Screen-negative 
(n= 70) 
Clinically- 
diagnosed 
(n = 70) 
Incident Rate Ratio, 
screening-detected 
vs screen-negative 
(95%CI) 
Incident Rate Ratio, 
clinically-diagnosed 
vs screening-detected 
(95%CI) 
Total observation, p-y 468.2 476.1 439.1   
Health care interactions      
Admissions, n 28 4 113   
Admissions per 1000 p-y 59.8 8.4 257.4 7.1 (2.5, 27.9) 4.3 (2.8, 6.8) 
Admission bed days 172 47 1069   
Admission bed days per 1000 p-y 367.3 98.7 2434.6 3.7 (2.7, 5.3) 6.6 (5.6, 7.8) 
Admissions, RHD-related, n 16 0 78   
Admissions, RHD-related per 1000 p-y 34.2 0 177.6 -- 5.2 (3.0, 9.5) 
Surgery, n 4 1 28   
Surgery per 1000 p-y 8.5 2.1 63.8 4.1 (0.4, 200.3) 7.5 (2.6, 29.2) 
Surgery, RHD-related, n 3 0 18   
Surgery, RHD-related per 1000 p-y 6.4 0 41.0 -- 6.4 (1.8, 33.9) 
Cardiac complications      
Congestive heart failure, n (%) 14 (20.0) 0 34 (48.6)   
Infective endocarditis, n 1  0 8    
Arrhythmia, n 1 1  3     
Stroke, n 0 0 2    
ARF, n 1  0 5    
Any complication, n (%) 14 (20.0) 1 (1.4) 39 (55.7)   
Any complication per 1000 p-y 29.9 2.1 88.8 14.2 (2.2, 601.9) 3.0 (1.6, 5.9) 
Mortality      
Mortality, n (%) 2 (2.9) 0 9 (12.9)   
Mortality per 1000 p-y 4.3 0 20.5 -- 4.8 (1.0, 45.6) 
Mortality, RHD-related, n (%) 1 (1.4) 0 9 (12.9)   
Mortality, RHD-related per 1000 p-y 2.1 0 20.5 -- 9.6 (1.3, 420.6) 
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p-y, person-years; RHD, rheumatic heart disease; ARF, acute rheumatic fever
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APPENDIX 
 TABLE A.1 – Clinical outcomes by diagnosis and sex. 
 
Screening-
detected 
Screen-
negative 
Clinically- 
diagnosed 
IRR clinically-diagnosed 
vs screening-detected 
(95%CI) 
Participants – n (observation p-y) 70 (468.2) 70 (476.1) 70 (439.1)  
Male  22 (152.0) 22 (152.0) 22 (147.1)  
Female 48 (316.2) 48 (324.1) 48 (292.0)  
Complications – n (per 1000 p-y) 14 (29.9) 1 (2.1) 39 (88.8) 3.0 (1.6, 5.9) 
Male  7 (46.1) 0 12 (81.6) 1.8 (0.6, 5.3) 
Female 7 (22.1) 1 (3.1) 27 (92.5) 4.2 (1.8, 11.4) 
Mortality – n (per 1000 p-y) 2 (4.3) 0 9 (20.5) 4.8 (1.0, 45.6) 
Male  0 0 2 (13.6) - 
Female 2 (6.3) 0 7 (24.0) 3.8 (0.7, 37.4) 
 
IRR, Incident Rate Ratio; p-y, person-years. 
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FIGURE LEGEND 
Fig 1. Cumulative RHD complications by cohort group 
Fig 2. Cumulative mortality by cohort group 
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Fig. 1 
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Fig. 2 
